Effects of Body Mass Index on the Hyperemic Response to Regadenoson
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
We will test the hypothesis that a single dose of Regadenoson will produce equivalent degrees
of coronary hyperemia in patients of widely different body size. This will be a prospective,
open-label, comparative trial using MRI to measure myocardial perfusion reserve (ratio of
myocardial blood flow with vasodilator to myocardial blood flow at rest) during sequential
administration of the coronary vasodilators adenosine and regadenoson. Non-invasive MRI
measurements of resting myocardial blood flow, and sequential measurements of blood flow
during adenosine infusion (weight adjusted dosing) and then blood flow during regadenoson
infusion (single, fixed dose. Blood flow measurements will be obtained sequentially and in
the same sequence in each subject during a two hour MRI exam. 32 subjects will be recruited
for this study. The first 2 will be for testing of the protocol. Inclusion criteria: 2
subjects for initial protocol evaluation, then 30 subjects with body mass index (BMI) between
18 and 40. Exclusions are pregnancy, renal dysfunction and claustrophobia.